StromaForte by Swedish StromaBio for Ageing: Likelihood of Approval
StromaForte is under clinical development by Swedish StromaBio and currently in Phase II for Ageing. According to GlobalData, Phase II drugs for Ageing does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the StromaForte LoA Report. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.StromaForte overviewThe therapeutic candidate is under development for the treatment of cardiovascular diseases, musculoskeletal injuries and degeneration, aging frailty and osteoarthritis. It consists of allogeneic bone marrow derived mesenchymal stromal cells (MSCs) administered through intravenous and intraarticular route.For a complete picture of StromaForte's drug-specific PTSR and LoA scores, buy the report here.
StromaForte is under clinical development by Swedish StromaBio and currently in Phase II for Ageing.
What's Your Reaction?
